|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Study on ceramide modulates EAAT-2 participation in the immunoinflammatory response in schizophrenia.
|
30915775 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association study of the excitatory amino acid transporter 2 (EAAT2) and glycine transporter 1 (GlyT1) gene polymorphism with schizophrenia in a Polish population.
|
31118638 |
2019 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Different studies reported that EAAT2 rs4354668 (-181 T/G) influences cognitive functions and brain structures in patients with schizophrenia.
|
30539765 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We explored this hypothesis by performing cell- and region-level studies of EAAT1 and EAAT2 expression in the mediodorsal nucleus of the thalamus in an elderly cohort of subjects with schizophrenia.
|
26416546 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results provide supportive evidence for an effect of SLC1A2 on the etiology of SCZ, suggesting that genetic variation (rs4354668 and its haplotypes) in SLC1A2 may be involved in impaired executive function, which adds to the current body of knowledge regarding the risk of SCZ and the impairment of cognitive performance.
|
26459047 |
2015 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in SLC1A2 has been implicated in a range of neurological and neuropsychiatric conditions including schizophrenia (SZ), autism and in core phenotypes of bipolar disorder (BD).
|
25406999 |
2015 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the glutamate transporters EAAT1 and EAAT2 and their isoforms have been implicated in schizophrenia.
|
26057049 |
2015 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Fifty schizophrenia patients underwent magnetic resonance and working memory testing outside of the scanner and were genotyped for rs4354668 EAAT2 polymorphism.
|
24076156 |
2014 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
In this study, we hypothesized that the protein complex formed by EAAT2, Na(+)/K(+) ATPase and mitochondrial proteins in human postmortem prefrontal cortex may be disrupted, leading to abnormal glutamate transmission in schizophrenia.
|
24560881 |
2014 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we hypothesized that the protein complex formed by EAAT2, Na(+)/K(+) ATPase and mitochondrial proteins in human postmortem prefrontal cortex may be disrupted, leading to abnormal glutamate transmission in schizophrenia.
|
24560881 |
2014 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia.
|
24076156 |
2014 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We found decreased expression of EAAT1 and EAAT2 protein in the superior temporal gyrus, and decreased EAAT2 protein in the hippocampus in schizophrenia.
|
23356950 |
2013 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found decreased expression of EAAT1 and EAAT2 protein in the superior temporal gyrus, and decreased EAAT2 protein in the hippocampus in schizophrenia.
|
23356950 |
2013 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Based on these data, we assessed possible effects of the -181T/G EAAT2 polymorphism on two core prefrontal cognitive performances, known to be impaired in schizophrenia, in a sample of 211 clinically stabilized patients.
|
22728822 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Based on these data, we assessed possible effects of the -181T/G EAAT2 polymorphism on two core prefrontal cognitive performances, known to be impaired in schizophrenia, in a sample of 211 clinically stabilized patients.
|
22728822 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The encoded proteins balance glutamate signalling vs. excitotoxicity in complex interactions involving the excitatory amino acid transporter 2 (EAAT2), implicated in the dysfunctional glutamatergic signalling in schizophrenia.
|
21281445 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found evidence for less glycosylation of both EAAT1 and EAAT2 in schizophrenia.
|
19716271 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we reinvestigated the association between SLC1A2 and schizophrenia by performing a case-control association study with twice as many subjects (401 cases and 407 controls) as compared to a previous study, and especially focused on the region where a previous association with schizophrenia had been shown.
|
19660525 |
2009 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 100 Japanese schizophrenics and 100 controls recruited from the Kyushu area for 11 single nucleotide polymorphism (SNP) markers distributed in the SLC1A2 region using the direct sequencing and pyrosequencing methods, and examined allele, genotype and haplotype association with schizophrenia.
|
15296513 |
2004 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The EAATs, normally expressed in both glia (EAAT1 and EAAT2) and neurons (EAAT3 and EAAT4), have previously been implicated in Huntington's disease, amyotrophic lateral sclerosis, and schizophrenia.
|
11850151 |
2002 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia.
|
9602129 |
1998 |